DK2729151T3 - Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf - Google Patents
Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf Download PDFInfo
- Publication number
- DK2729151T3 DK2729151T3 DK12730993.8T DK12730993T DK2729151T3 DK 2729151 T3 DK2729151 T3 DK 2729151T3 DK 12730993 T DK12730993 T DK 12730993T DK 2729151 T3 DK2729151 T3 DK 2729151T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- applications
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161505598P | 2011-07-08 | 2011-07-08 | |
PCT/EP2012/062922 WO2013007557A1 (en) | 2011-07-08 | 2012-07-03 | Pharmaceutical composition, methods for treating and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2729151T3 true DK2729151T3 (da) | 2021-06-28 |
Family
ID=46420221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12730993.8T DK2729151T3 (da) | 2011-07-08 | 2012-07-03 | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf |
Country Status (22)
Country | Link |
---|---|
US (5) | US20130035298A1 (da) |
EP (2) | EP2729151B1 (da) |
JP (2) | JP2014520778A (da) |
KR (1) | KR20140041697A (da) |
CN (2) | CN106692126A (da) |
AR (1) | AR087729A1 (da) |
AU (1) | AU2012283229B2 (da) |
BR (1) | BR112014000380A2 (da) |
CA (1) | CA2837787C (da) |
CY (1) | CY1124307T1 (da) |
DK (1) | DK2729151T3 (da) |
EA (1) | EA025497B1 (da) |
ES (1) | ES2871904T3 (da) |
HR (1) | HRP20210978T1 (da) |
HU (1) | HUE054621T2 (da) |
LT (1) | LT2729151T (da) |
MX (1) | MX2014000010A (da) |
PL (1) | PL2729151T3 (da) |
PT (1) | PT2729151T (da) |
RS (1) | RS61827B1 (da) |
SI (1) | SI2729151T1 (da) |
WO (1) | WO2013007557A1 (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
WO2010092125A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
PT2486029E (pt) | 2009-09-30 | 2015-10-14 | Boehringer Ingelheim Int | Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo |
UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
ES2702174T3 (es) | 2013-04-05 | 2019-02-27 | Boehringer Ingelheim Int | Usos terapéuticos de empagliflozina |
CA2812519A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EA033286B1 (ru) | 2013-04-18 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ лечения или отсрочки развития хронической болезни почек |
US9902751B2 (en) | 2013-12-30 | 2018-02-27 | Mylan Laboratories Limited | Process for the preparation of empagliflozin |
KR20220097538A (ko) * | 2014-01-23 | 2022-07-07 | 베링거잉겔하임베트메디카게엠베하 | 개과 동물에서 대사 장애의 치료 |
EP3113802A1 (en) * | 2014-03-04 | 2017-01-11 | Otsuka Pharmaceutical Co., Ltd. | Iohexol powder and method of using the same |
US20170319539A1 (en) * | 2014-10-01 | 2017-11-09 | Mylan Laboratories Ltd. | Amorphous Empagliflozin |
WO2016156124A1 (en) * | 2015-03-27 | 2016-10-06 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation comprising sembragiline |
KR20230028568A (ko) * | 2016-03-16 | 2023-02-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 엠파글리플로진을 포함하는 약제학적 조성물 및 이의 용도 |
WO2018087132A1 (en) * | 2016-11-10 | 2018-05-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2020089760A1 (en) * | 2018-11-01 | 2020-05-07 | Glenmark Pharmaceuticals Limited | Fixed dose pharmaceutical composition comprising combination of remogliflozin or salt or ester thereof and vildagliptin or salt thereof |
US11655240B1 (en) * | 2022-05-10 | 2023-05-23 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
CN103435581B (zh) | 2004-03-16 | 2015-08-19 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
ES2314743T3 (es) | 2004-12-16 | 2009-03-16 | Boehringer Ingelheim International Gmbh | Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion. |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
PT1881850E (pt) | 2005-05-13 | 2010-11-26 | Lilly Co Eli | Compostos peguilados de glp-1 |
EP1924571B1 (en) | 2005-08-30 | 2010-10-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
RU2008113050A (ru) | 2005-09-08 | 2009-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
TW200801029A (en) | 2006-02-15 | 2008-01-01 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
WO2008055870A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
NZ598778A (en) | 2006-11-09 | 2013-09-27 | Boehringer Ingelheim Int | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions |
EP2185178B1 (en) | 2007-08-03 | 2017-08-23 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
WO2010092125A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
SG173587A1 (en) * | 2009-02-13 | 2011-09-29 | Boehringer Ingelheim Int | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia |
UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
PT2486029E (pt) | 2009-09-30 | 2015-10-14 | Boehringer Ingelheim Int | Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo |
EP2483286B1 (en) | 2009-09-30 | 2016-07-13 | Boehringer Ingelheim International GmbH | Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
-
2012
- 2012-07-02 US US13/539,713 patent/US20130035298A1/en not_active Abandoned
- 2012-07-03 MX MX2014000010A patent/MX2014000010A/es active IP Right Grant
- 2012-07-03 LT LTEP12730993.8T patent/LT2729151T/lt unknown
- 2012-07-03 SI SI201231915T patent/SI2729151T1/sl unknown
- 2012-07-03 PL PL12730993T patent/PL2729151T3/pl unknown
- 2012-07-03 PT PT127309938T patent/PT2729151T/pt unknown
- 2012-07-03 DK DK12730993.8T patent/DK2729151T3/da active
- 2012-07-03 CN CN201611176372.5A patent/CN106692126A/zh active Pending
- 2012-07-03 CN CN201280038791.6A patent/CN103732230A/zh active Pending
- 2012-07-03 EP EP12730993.8A patent/EP2729151B1/en not_active Revoked
- 2012-07-03 EA EA201400119A patent/EA025497B1/ru not_active IP Right Cessation
- 2012-07-03 JP JP2014517770A patent/JP2014520778A/ja active Pending
- 2012-07-03 EP EP21157166.6A patent/EP3854404A1/en active Pending
- 2012-07-03 WO PCT/EP2012/062922 patent/WO2013007557A1/en active Application Filing
- 2012-07-03 AU AU2012283229A patent/AU2012283229B2/en active Active
- 2012-07-03 KR KR1020147000445A patent/KR20140041697A/ko not_active Application Discontinuation
- 2012-07-03 ES ES12730993T patent/ES2871904T3/es active Active
- 2012-07-03 HU HUE12730993A patent/HUE054621T2/hu unknown
- 2012-07-03 BR BR112014000380A patent/BR112014000380A2/pt not_active IP Right Cessation
- 2012-07-03 CA CA2837787A patent/CA2837787C/en active Active
- 2012-07-03 RS RS20210582A patent/RS61827B1/sr unknown
- 2012-07-06 AR ARP120102475A patent/AR087729A1/es unknown
-
2016
- 2016-01-07 JP JP2016001599A patent/JP2016121156A/ja active Pending
-
2018
- 2018-03-27 US US15/936,927 patent/US20180214468A1/en not_active Abandoned
-
2019
- 2019-11-26 US US16/695,324 patent/US20200268777A1/en not_active Abandoned
-
2021
- 2021-06-14 US US17/346,475 patent/US20220096505A1/en not_active Abandoned
- 2021-06-14 CY CY20211100523T patent/CY1124307T1/el unknown
- 2021-06-19 HR HRP20210978TT patent/HRP20210978T1/hr unknown
-
2023
- 2023-09-06 US US18/461,850 patent/US20230405032A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RS61827B1 (sr) | 2021-06-30 |
CA2837787C (en) | 2021-09-14 |
AR087729A1 (es) | 2014-04-16 |
HUE054621T2 (hu) | 2021-09-28 |
PL2729151T3 (pl) | 2021-10-18 |
ES2871904T3 (es) | 2021-11-02 |
CN103732230A (zh) | 2014-04-16 |
AU2012283229A1 (en) | 2014-01-09 |
US20180214468A1 (en) | 2018-08-02 |
LT2729151T (lt) | 2021-05-25 |
EP2729151B1 (en) | 2021-03-31 |
JP2014520778A (ja) | 2014-08-25 |
CA2837787A1 (en) | 2013-01-17 |
MX2014000010A (es) | 2014-02-27 |
BR112014000380A2 (pt) | 2017-02-14 |
AU2012283229B2 (en) | 2017-06-15 |
PT2729151T (pt) | 2021-05-25 |
US20230405032A1 (en) | 2023-12-21 |
EP2729151A1 (en) | 2014-05-14 |
KR20140041697A (ko) | 2014-04-04 |
US20200268777A1 (en) | 2020-08-27 |
SI2729151T1 (sl) | 2021-06-30 |
CN106692126A (zh) | 2017-05-24 |
HRP20210978T1 (hr) | 2021-09-17 |
WO2013007557A1 (en) | 2013-01-17 |
EA025497B1 (ru) | 2016-12-30 |
US20130035298A1 (en) | 2013-02-07 |
EP3854404A1 (en) | 2021-07-28 |
CY1124307T1 (el) | 2022-07-22 |
NZ618546A (en) | 2016-02-26 |
JP2016121156A (ja) | 2016-07-07 |
EA201400119A1 (ru) | 2014-08-29 |
US20220096505A1 (en) | 2022-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2729151T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
SMT201700008B (it) | Composizione farmaceutica | |
BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
DK2768958T3 (da) | Kationiske aminlipider og anvendelser deraf | |
DK3608325T3 (da) | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
DK2906684T3 (da) | T-celle-modificerende forbindelser og anvendelser deraf | |
DK2986304T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf. | |
DK2694038T3 (da) | Farmaceutisk sammensætning | |
DK2699397T3 (da) | Apparater, system og fremgangsmåder til at danne pressede artikler og pressede artikler dannet derved | |
DK2920149T3 (da) | 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf | |
DK2699553T3 (da) | Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed | |
DK2763665T3 (da) | Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf | |
DK3246018T3 (da) | Farmaceutisk sammensætning | |
DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
BR112014010290A2 (pt) | composição farmacêutica, métodos, composições e usos | |
BR112015003259A2 (pt) | composto, composição farmacêutica, e, composição de vacina. | |
DK2758349T3 (da) | Vanadiumbaserede frittematerialer og fremgangsmåder til fremstilling heraf | |
BR112013014644A2 (pt) | composição farmacêutica e complexo | |
EE201300005A (et) | Ravimkoostis | |
BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
DK3199533T3 (da) | Pyrazolforbindelse og farmaceutisk anvendelse deraf | |
DK2917181T3 (da) | Heteroarylderivater og anvendelser deraf | |
DK2897594T3 (da) | Farmaceutisk sammensætning | |
DK2745849T3 (da) | Polydeoxyribonukleotidsammensætning og anvendelser deraf | |
DK2704744T3 (da) | Komplementfaktor-b-analoger og anvendelser deraf |